Please ensure Javascript is enabled for purposes of website accessibility

FDA Warns Public About Inaccuracy Issues With Abbott's Coronavirus Test

By Cory Renauer – May 15, 2020 at 11:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Adverse event reports suggest the Abbott ID NOW test has been delivering a troubling number of false negative results.

The U.S. Food and Drug Administration alerted the public on Thursday evening that Abbott's (ABT 0.29%) ID NOW coronavirus test could have some serious issues. After receiving 15 adverse event reports the FDA issued a warning that the test could be delivering negative results to people who actually are COVID-19 positive.

The FDA says Abbott's rapid point-of-care test can still be used to correctly identify many positive cases in minutes. Negative results from patients that display any symptoms, though, need to be confirmed with older molecular diagnostics that slowly amplify genetic material with an old-fashioned incubation process. 

Close up of sample tubes.

Image source: Getty Images.

The pre-published blues 

The FDA's warning was preceded by disturbing results from a study that hasn't been peer-reviewed yet. Researchers from NYU Langone Health ran samples from over 100 patients through Abbott's ID NOW COVID-19 test and then ran the same samples through another rapid point-of-care diagnostic, the Cepheid Xpert Xpress SARS-CoV-2 test using a variety of sample collection techniques. Depending on the technique used, Abbott's test missed between one-third and 48% of the samples that tested positive with Cepheid's test.

While the NYU study results are troubling, Abbott contends the NYU study wasn't consistent with other studies that suggest the ID NOW COVID-19 diagnostic catches around 90% of positives when used in close proximity to patients as intended. It's also important to understand the ID NOW COVID-19 test wasn't intended to screen asymptomatic people.

To address these sensitivity concerns, Abbott has agreed to conduct post-market studies with at least 150 COVID-19 positive patients. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$103.38 (0.29%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.